News:
04-Mar-2013: Crossbeta Biosciences announced that it has successfully secured funding to execute its plans for the next years. This financing round is based on investments by new as well as existing shareholders and includes an Innovation Grant from AgentschapNL. The proceeds will be used to further advance Crossbeta’s drug screening technology platform in several therapeutic areas where misfolded proteins play a role in the pathology and to establish drug discovery partnerships. Read the full release (also in pdf format).
Watch a short presentation about Crossbeta's activities:
Learn about our Alzheimer's program in two minutes: have a look at a short presentation by our CEO Guus Scheefhals.
CROSSBETA
Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta's oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer's, Parkinson's, Huntington and Diabetes Type 2.
In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50% neutralizing effect on oligomer-induced neurotoxicity.
Stable oligomers can also be used as reference in biomarker assays.
Where you can meet us:
- Alpha-synuclein in Parkinson’s Disease and related neurodegenerative diseases International Conference, March 2 and 3, Dubai, VAE
- Alzheimer’s and Parkinson’s 11th International Congres, March 6-10, Florence, Italy
- BIO Europe Spring, March 11-13, Barcelona, Spain.
- BIO International Convention, April 22-25, Chicago, USA.
Vacancy:
Crossbeta has a vacancy for a Research analist